- Home
- IHD vs AGEN Comparison
IHD vs AGEN Comparison
Compare IHD & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHD
- AGEN
- Stock Information
- Founded
- IHD 2011
- AGEN 1994
- Country
- IHD United States
- AGEN United States
- Employees
- IHD N/A
- AGEN N/A
- Industry
- IHD Investment Managers
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IHD Finance
- AGEN Health Care
- Exchange
- IHD Nasdaq
- AGEN Nasdaq
- Market Cap
- IHD 89.7M
- AGEN 96.2M
- IPO Year
- IHD N/A
- AGEN 2000
- Fundamental
- Price
- IHD $5.08
- AGEN $3.48
- Analyst Decision
- IHD
- AGEN Buy
- Analyst Count
- IHD 0
- AGEN 3
- Target Price
- IHD N/A
- AGEN $10.50
- AVG Volume (30 Days)
- IHD 27.7K
- AGEN 419.4K
- Earning Date
- IHD 01-01-0001
- AGEN 03-13-2025
- Dividend Yield
- IHD 10.32%
- AGEN N/A
- EPS Growth
- IHD N/A
- AGEN N/A
- EPS
- IHD N/A
- AGEN N/A
- Revenue
- IHD N/A
- AGEN $160,427,000.00
- Revenue This Year
- IHD N/A
- AGEN N/A
- Revenue Next Year
- IHD N/A
- AGEN $36.13
- P/E Ratio
- IHD N/A
- AGEN N/A
- Revenue Growth
- IHD N/A
- AGEN 59.00
- 52 Week Low
- IHD $4.49
- AGEN $2.50
- 52 Week High
- IHD $5.47
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- IHD 48.45
- AGEN 58.60
- Support Level
- IHD $5.01
- AGEN $3.08
- Resistance Level
- IHD $5.17
- AGEN $3.29
- Average True Range (ATR)
- IHD 0.06
- AGEN 0.26
- MACD
- IHD 0.00
- AGEN 0.05
- Stochastic Oscillator
- IHD 59.09
- AGEN 80.36
About IHD Voya Emerging Markets High Income Dividend Equity Fund
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).